Stand Up To Cancer (SU2C) with its Scientific Partner, the American Association of Cancer Research (AACR), announced today that Laurie H. Glimcher, MD, President and CEO of Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School is the newest member of the SU2C Scientific Advisory Committee. Glimcher was introduced as the Scientific Advisory Committee's newest member at the SU2C annual Scientific Summit in Santa Monica.
"Dr. Glimcher is a distinguished scientist and powerful leader in cancer research," said Scientific Advisory Committee Chair Phillip A. Sharp, PhD, Institute professor, Koch Institute for Integrative Cancer Research of the Massachusetts Institute of Technology (MIT), and a Nobel laureate. "Her willingness to serve as a member of the Scientific Advisory Committee, considering her many responsibilities as head of the Dana-Farber Cancer Institute, is a strong testament of Stand Up To Cancer's value to the community."
The SU2C Scientific Advisory Committee is composed of prestigious academic and industry leaders in cancer research. Its role is to provide insight and guidance to SU2C as an organization, setting the direction for its research initiatives, reviewing proposals for new grant awards and conducting rigorous oversight of all active grants in the SU2C portfolio.
Glimcher is internationally recognized for her research in identifying key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. Glimcher is a Member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society, Fellow of the American Academy of Arts and Sciences, and the former President of the American Association of Immunologists.
In addition to her research efforts, Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed as dean of Weill Cornell Medicine in New York and is the first female President and CEO of Dana-Farber Cancer Institute in Boston.
"We are honored that Dr. Glimcher has agreed to join the Scientific Advisory Committee to help guide SU2C's extensive research portfolio," said Sung Poblete, PhD, RN, CEO of SU2C. "Her leadership and expertise will be critical in diversifying SU2C's scientific programming, paving the way for breakthrough research, and as SU2C implements its health equity initiative to improve diversity in cancer clinical trials, all contributing to better outcomes for patients everywhere."
